BOARD OF DIRECTORS
DAVID RUBENSTEIN
|
Following a distinguished career in academia and years of experience in the pharmaceutical industry, Dr. Rubenstein joined Dermavant as Chief Scientific Officer in March 2018 from GlaxoSmithKline Dermatology. At GSK, he built an industry-leading dermatology drug development organization as VP, Discovery and Preclinical Development. Prior to GSK, Dr. Rubenstein held academic roles at the University of North Carolina at Chapel Hill, most recently serving as the Louis C. Skinner Jr. Distinguished Professor of Dermatology. Dr. Rubenstein received his A.B. in Molecular Biology from Princeton University and his M.D. and Ph.D. from Duke University School of Medicine. He completed his dermatology residency and postdoctoral fellowship in dermatology and biology at UNC-Chapel Hill.
|
JIM LEE
|
Jim Lee is a physician scientist with over 23 years in drug development. He joined Incyte in 2018 to lead the Inflammation and AutoImmunity (IAI) development group. Prior to joining Incyte, Jim worked in clinical development and medical affairs at a number of dermatology focused biotech and pharmaceutical companies including GlaxoSmithKline, Graceway Pharmaceuticals and Dermavant Sciences. He has been involved in the development of a number of approved drugs, including imiquimod, tapinarof, ustekinumab; and ruxolitinib cream.
|
|